El interés en corto de BGM Group da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de BGM Group. Los datos de interés en corto se actualizan cada dos semanas.

BGM Group (NASDAQ:BGM) Bolsa, Informe de interés en corto

Qilian Intl Hldg Gr

BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.

Oil,Field,Site,,In,The,Evening,,Oil,Pumps,Are,Running

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ATER

OABI

ONVO

Las acciones en EE. UU. suben a mitad de jornada, lideradas por un crecimiento en energía. El Dow sube 200 pts y el petróleo repunta.

Wall Street en alza: Dow sube 200 puntos mientras el petróleo y el oro se mantienen firmes

BGM Group Ltd

BG Medicine Inc

BERGAMO AQUISITION CORP by Bergamo Acquisition Corp.

HC Wainwright &amp; Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) with a Buy and maintains $34 price target.

Price Target

Reiteration

Analyst Ratings

RGNX

HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Buy and maintains $16 price target.

ESPR

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

Caleres, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAL#NYSE">CAL</a>) shares are trading higher after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44412721/caleres-reports-fourth-quarter-full-year-results-and-provides-2025-outlook" rel="noreferrer noopener">reported&nbsp;fourth-quarter results</a>.
Revenues fell 8.3% year over year to $639.2&nbsp;million, missing&nbsp;the analyst consensus of&nbsp;$653.86 million.
Famous Footwear sales fell&nbsp;9.6%&nbsp;Y/Y, with comparable store sales down 2.9%. Brand Portfolio sales decreased&nbsp;7.2%&nbsp;in the quarter.
&#8220;Famous Footwear&#8217;s business softened in the quarter, but we maximized key selling periods. We invested to support our long-term growth while continuing to evolve our supply chain and further mitigate the impact of additional tariffs,&#8221; said Jay Schmidt, president and chief executive officer.
The company&#8217;s gross margin rate contracted 80&nbsp;basis points year over year to&nbsp;43.0% and adjusted EBITDA fell to $29.0 million.
Adjusted EPS of&nbsp;33 cents&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus of&nbsp;24 cents</a>.
In 2024, Caleres returned $74.7 million in cash to shareholders through dividends and share repurchases. Borrowings under the revolving credit facility totaled $219.5 million at the end of the period.
&#8220;As we look forward to 2025 and the macroeconomic environment with persistent inflation and newer tariffs, we believe it is prudent to take a conservative view for the year,&#8221; added Schmidt.
Outlook: The company expects FY25 net sales to decline by&nbsp;1% to up 1%&nbsp;and EPS of <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$2.80 &#8211; $3.20&nbsp;(consensus&nbsp;$3.21)</a>.
For the first quarter, Caleres expects sales to decline 5% – 6% and EPS of&nbsp;$0.35 &#8211; $0.40&nbsp;vs.&nbsp;consensus of $0.87.
Caleres said it currently expects&nbsp;75%&nbsp;of its Brand Portfolio, and an even greater percentage of Lead Brands&#8217; sourcing to be outside of China by the second half of 2025.
Last month, the company inked a deal to acquire Stuart Weitzman&nbsp;from&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43820457/footwear-firm-calere-steps-into-luxury-105-million-stuart-weitzman-deal-set-for-2025-close" rel="noreferrer noopener">Tapestry </a><a target="_blank" href="https://www.benzinga.com/25/02/43820457/footwear-firm-calere-steps-into-luxury-105-million-stuart-weitzman-deal-set-for-2025-close" rel="noreferrer noopener">for $105 million</a>.&nbsp;The guidance excludes this acquisition, which is expected to close in the summer of 2025.
Price Action: CAL shares are down 2.46% at $15.99 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44414695/temu-parent-pdd-holdings-drops-after-q4-revenue-miss-details" target="_blank" rel="noreferrer noopener">Temu Parent PDD Holdings Drops After Q4 Revenue Miss: Details</a></li>
</ul>
Image via Shutterstock.

Guidance

Small Cap

Caleres Reports Lower Q4 Sales, Cautious Outlook For 2025 Amid Inflation And Tariffs

Pure Storage's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) short percent of float has fallen 22.35% since its last report. The company recently reported that it has 9.16 million shares sold short, which is 3.51% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.68 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Pure Storage Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484630_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pure Storage has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Pure Storage's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Pure Storage's peer group average for short interest as a percentage of float is 8.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PSTG

Is Pure Storage Gaining or Losing Market Support?

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has risen 3.1% since its last report. The company recently reported that it has 22.93 million shares sold short, which is 1.33% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.23%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Abbott Laboratories?

Penumbra's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has fallen 19.16% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484619_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Penumbra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.07%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Penumbra's Recent Short Interest

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 15.88%. Currently, UnitedHealth Group has a market capitalization of $465.40 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $4,307.40 today based on a price of $508.79 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742484611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Morgan Stanley analyst Stephen Byrd maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Equal-Weight and raises the price target from $75 to $78.

Morgan Stanley Maintains Equal-Weight on Xcel Energy, Raises Price Target to $78

Morgan Stanley analyst Stephen Byrd maintains Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) with a Equal-Weight and raises the price target from $75 to $78.

Morgan Stanley Maintains Equal-Weight on Spire, Raises Price Target to $78

JP Morgan analyst John Ivankoe maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Underweight and lowers the price target from $55 to $48.

CAKE

JP Morgan Maintains Underweight on Cheesecake Factory, Lowers Price Target to $48

Morgan Stanley analyst Stephen Byrd maintains Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Equal-Weight and raises the price target from $88 to $91.

Morgan Stanley Maintains Equal-Weight on Southern, Raises Price Target to $91

Morgan Stanley analyst David Arcaro maintains Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) with a Overweight and raises the price target from $85 to $86.

Morgan Stanley Maintains Overweight on Sempra, Raises Price Target to $86

Morgan Stanley analyst David Arcaro maintains Public Service Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>) with a Overweight and raises the price target from $96 to $100.

Morgan Stanley Maintains Overweight on Public Service Enterprise, Raises Price Target to $100

JP Morgan analyst John Ivankoe maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Neutral and lowers the price target from $185 to $184.

TXRH

JP Morgan Maintains Neutral on Texas Roadhouse, Lowers Price Target to $184

On Thursday, PTC Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Annual Clinical Genetics Meeting</a>.
These data provide further evidence of the potential benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU) patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42272846/ptc-therapeutics-inks-licensing-pact-with-novartis-worth-3-billion-for-huntingtons-program" rel="noreferrer noopener">PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington&#8217;s Program</a>
Phenylketonuria is an inherited disorder that increases the levels of a substance called <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44414358/ptc-therapeutics-presents-new-sepiapterin-data-from-ongoing-studies" rel="noreferrer noopener">phenylalanine in the blood</a>.
Untreated phenylketonuria can lead to brain damage, intellectual disabilities, behavioral symptoms or seizures.
&#8220;These new data provide further evidence of the meaningful benefit sepiapterin can provide for children and adults with PKU, including those with the most severe form of the disease,&#8221; said Matthew Klein, CEO of PTC Therapeutics. &#8220;Furthermore, the treatment benefit demonstrated in individuals with mutations not responsive to BH4 and consistent with classical disease phenotype support the potential to penetrate all key patient segments.&#8221;
Treatment includes a strict diet with limited protein.
Key data presented include:
<ul>
<li>Over 97% of subjects participating in the Phe tolerance protocol of the APHENITY open-label extension study demonstrate the ability to liberalize their diet while on sepiapterin treatment, with a mean increase in protein intake of 126%.</li>
<li>66% of subjects participating in the Phe tolerance sub study reached or exceeded the age-adjusted recommended daily allowance of protein intake for an individual without PKU, while maintaining control of blood Phe levels.</li>
<li>Genetic variant analysis of subjects participating in the APHENITY study demonstrates that over 70% had a Genotype-Phenotype Value (GPV) consistent with classical PKU.</li>
</ul>
PTC submitted FDA regulatory approval applications in 2024 for sepiapterin for children and adults with PKU, with a target regulatory <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44024275/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2024-financial" rel="noreferrer noopener">action date of&nbsp;July 29, 2025</a>.
PTC also submitted several additional marketing authorization applications outside the U.S. for sepiapterin in 2024. The CHMP opinion on sepiapterin MAA is expected in the second quarter of 2025. A regulatory decision in Japan is expected in the fourth quarter of 2025.
Price Action: PTCT stock is down 0.18% at $56.88 on Thursday&#8217;s last check.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/buybacks/25/03/44415887/veon-reports-4-7-q4-sales-growth-as-digital-push-accelerates-eyes-double-digit-gains-in-2025" target="_blank" rel="noreferrer noopener">VEON Reports 4.7% Q4 Sales Growth As Digital Push Accelerates, Eyes Double-Digit Gains In 2025</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

PTCT

PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July

Morgan Stanley analyst David Arcaro maintains PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Overweight and raises the price target from $35 to $38.

Morgan Stanley Maintains Overweight on PPL, Raises Price Target to $38

Popular meme coin Fartcoin (CRYPTO: FARTCOIN) is rebounding, leading to renewed optimism among traders for a <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43059996/fartcoin-jumps-15-trader-predicts-dogecoin-style-parabolic-run">sustained meme coin rally</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>&nbsp;$0.3912</td>
<td>$391.3 million</td>
<td>+13.4%&nbsp;</td>
<td>&nbsp;+43.3</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1739</td>
<td>$25.8 billion</td>
<td>+0.9%&nbsp;</td>
<td>+3.1%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001294</td>
<td>$7.6 billion</td>
<td>+1%&nbsp;</td>
<td>+6.7%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Unipcs <a href="https://x.com/theunipcs/status/1902456168754376885">indicated</a> he is up seven figures on his Fartcoin long. 
Despite being 85% down from all-time highs, he believes strong meme coins recover sharply. According to the trader, Fartcoin has still one of the &#8220;biggest mindshares,&#8221; with the rebund being an indicator thereof.
"If the bull run continues, a return to all-time highs is a matter of when, not if," he said.
Another trade sees Fartcoin in an accumulation phase, a critical period where big money is made. 
He argues that risk-reward is best now, not when the price reaches $2. "The only skill you need now is patience," he concluded.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$FARTCOIN I don't have any idea about how long this accumulation is going to last but this is how bottoms are formed and where money is made. Now it's when R:R actually looks best, not at $2. Only skill you need now is patience. <a href="https://t.co/WFGdgd9TmI">pic.twitter.com/WFGdgd9TmI</a>
&mdash; Res (@resdegen) <a href="https://twitter.com/resdegen/status/1902620937096253798?ref_src=twsrc%5Etfw">March 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44399122/pepe-fartcoin-bonk-leapfrog-dogecoin-shiba-inu-in-momentum-as-traders-predict-bullish-momentum">Pepe, Fartcoin, Bonk Leapfrog Dogecoin, Shiba Inu In Momentum As Traders Predict Bullish Momentum</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$SHIB

Fartcoin Soars 13% In A Day Outpacing Dogecoin, Shiba Inu: Is A Return To All-Time Highs In The Cards?

Morgan Stanley analyst David Arcaro maintains Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Equal-Weight and raises the price target from $84 to $88.

Morgan Stanley Maintains Equal-Weight on Pinnacle West Capital, Raises Price Target to $88

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher on continued strength following Wednesday's Fed decision. Additionally, US Feb. existing home sales beat expectations.

JP Morgan analyst John Ivankoe maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Underweight and lowers the price target from $107 to $105.

Comments

BGM Group

Interés en corto

BGM Group (NASDAQ:BGM) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL